Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis

Du, Yiqi; Pahernik, Sascha; Hadaschik, Boris; Teber, Doğu; Duensing, S.; Jäger, Dirk; Hohenfellner, Markus; Grüllich, Carsten

doi:10.1016/j.urolonc.2016.05.017

Cited by 23 publications

(24 citation statements)

References 17 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the survival time after metastasis is about 12 months for mRCC patients (6). There were studies found that the prognosis of RCC patients with bone metastasis is closely related to age, TNM stage, other organ metastasis, whether receive targeted treatment (7,8). However, these predictions have not been validated effectively due to the rarity of the disease and there is still a lack of a predictive model that calculates different variables simultaneously.…”

Section: Introductionmentioning

confidence: 99%

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Wang

et al. 2021

Int. braz j urol.

View full text Add to dashboard Cite

Purpose: Increased attention has been focused on the survival of renal cell carcinoma (RCC) patients with bone metastasis. This study proposed to establish and evaluate a nomogram for predicting the overall survival (OS) and cancer-specific survival (CSS) of RCC patients with bone metastasis. Materials and Methods: RCC patients with bone metastasis between 2010 and 2015 were captured from the surveillance, epidemiology and end results (SEER) database. Univariate and multivariate cox regressions were performed to assess the effects of clinical variables on OS and CSS. The nomogram based on the Cox hazards regression model was developed. Concordance index (C-index) and calibration curve were performed to evaluate the accuracy of nomogram models, receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were conducted to assess the predict performance. Results: A total of 2.471 eligible patients were enrolled in this study. The patients were assigned to primary (n=1.672) and validation (n=799) cohorts randomly. The 1-, 2-, and 3-year OS and CSS nomogram models were constructed based on age at diagnosis, sex, marital status, pathological grade, T-stage, N-stage, brain/liver/lung metastasis, surgery, radiotherapy and chemotherapy. The c for OS and CSS prediction was 0.730 (95% confidence interval [CI]: 0.719-0.741) and 0.714 (95%CI:0.702-0.726). The calibration curves showed significant agreement between nomogram models and actual observations. ROC and DCA indicated nomograms had better predict performance. Conclusions: The nomograms for predicting prognosis provided an accurate prediction of OS and CSS in RCC patients with bone metastasis, and contributed clinicians to optimize individualized treatment plans.

show abstract

Section: Introductionmentioning

confidence: 99%

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Wang

et al. 2021

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…Both identified a solitary site of bone metastasis as a strong predictor of overall survival. A more recent published series included 33 patients who underwent surgical resection with or without radiation, plus systemic targeted therapy [17]. Median OS was 39.1 months for surgical resection versus 7.6 months for 59 patients with bone metastases who did not undergo surgery.…”

Section: Bonementioning

confidence: 99%

Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review

Achkar

Maranchie

Appleman

2019

KCA

View full text Add to dashboard Cite

Introduction: Metastasectomy for advanced renal cell carcinoma has been practiced for over 80 years. However, there is uncertainty regarding the clinical benefit of this procedure and the optimum selection of appropriate patients. Materials and Methods: A systematic literature search was conducted according to the PRISMA statement to identify studies that reported outcomes in patients who underwent metastasectomy at any time. Primary endpoints were overall and disease-free survival. Radiation therapy studies were not included. Case reports and series with less than 20 patients were not included. Results: Forty-four studies were identified that met the criteria for inclusion, with a total of 4195 patients. No studies that randomized patients to surgery versus no surgery were identified. Disease-free interval, number of metastatic sites and completeness of resection were prognostic for overall survival in many of the included studies. Seventeen studies included patients with lung metastases only (1465 patients in total). Conclusions: Case series have documented patients with prolonged disease-free interval and survival after metastasectomy. However, without randomized data, the impact of metastasectomy on outcomes in patients with metastatic renal cell carcinoma (mRCC) remains unknown, especially in the evolving landscape of systemic therapies.

show abstract

“…( 1 ). A total of 25–30% of newly diagnosed renal RCC cases present with metastases ( 2 ), and 20–40% of patients with locally limited RCC undergo relapse during the follow-up period, even if the tumors are surgically resected ( 3 ). Moreover, with regards to metastatic RCC, 30% of patients have bone metastasis ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma

et al. 2020

View full text Add to dashboard Cite

Enlarged bone metastasis from renal cell carcinoma (RCC) can cause skeletal-related events, and thus treatment to inhibit the growth of bone metastases is often required. Although radiotherapy for RCC bone metastases can achieve a certain degree of local control, evidence is lacking regarding the effects of systemic therapy to improve bone metastasis. The present study aimed to assess the treatment efficacy of targeted therapy and immune checkpoint inhibitors, and to determine whether systemic therapy without radiotherapy can shrink bone metastases of RCC. The present study retrospectively reviewed 44 patients with RCC with bone metastases treated via systemic therapy, including targeted therapy or immune checkpoint inhibitors. Patients were divided into two groups: Those who underwent systemic therapy with radiotherapy for bone lesions (n=29); and those who underwent systemic therapy without radiotherapy for bone lesions (n=15). The radiographical efficacy of systemic therapy and the time to progression of bone metastases were compared between groups. The overall response rate of systemic therapy with radiotherapy was 44%, and in total, 13 patients demonstrated a partial response. Only one patient (6%) had a partial response among those who were treated via systemic therapy without radiotherapy. The time to progression of bone metastasis was 9.5 and 2.1 months in patients treated with and without radiotherapy, respectively (P<0.0001). Collectively, the present results suggested that targeted therapy or immune checkpoint inhibitors without radiotherapy had only a slight effect on bone metastasis control.

show abstract

Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis

Cited by 23 publications

References 17 publications

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma

Contact Info

Product

Resources

About